Comparative Pharmacology
Head-to-head clinical analysis: OSELTAMIVIR PHOSPHATE versus RAPIVAB.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OSELTAMIVIR PHOSPHATE versus RAPIVAB.
OSELTAMIVIR PHOSPHATE vs RAPIVAB
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Oseltamivir phosphate is a neuraminidase inhibitor. It is a prodrug that is hydrolyzed to the active metabolite oseltamivir carboxylate, which inhibits influenza A and B neuraminidases, preventing viral replication by blocking the cleavage of sialic acid residues and release of progeny virions.
Neuraminidase inhibitor; inhibits influenza virus neuraminidase, preventing viral replication and release from infected cells.
75 mg orally twice daily for 5 days.
200 mg IV as a single dose infused over 30 minutes.
None Documented
None Documented
Oseltamivir carboxylate: 6-10 hours (terminal) in adults with normal renal function; prolonged to >20 hours in severe renal impairment (CrCl <10 mL/min).
Terminal elimination half-life is approximately 24-30 hours in healthy adults; prolonged in renal impairment (up to 40-60 hours in severe cases), supporting once-daily dosing.
Renal: 60-70% of total clearance as oseltamivir carboxylate via glomerular filtration and tubular secretion; unchanged oseltamivir <5%. Fecal: <20% as oseltamivir carboxylate. Biliary: negligible.
Primarily renal as unchanged drug via glomerular filtration and tubular secretion; ~70% excreted unchanged in urine over 24 hours, with ~30% undergoing hepatic metabolism via glucuronidation followed by biliary excretion.
Category A/B
Category C
Neuraminidase Inhibitor
Neuraminidase Inhibitor